Why These Five Stocks Are Trending on Tuesday

CONSOL Rises Despite Soft Results

The market is in a forgiving mood when it comes to CONSOL Energy Inc. (NYSE:CNX). Although the coal and natural gas company reported a second-quarter loss of $0.21 per share on sales of $285.8 million, versus estimates of a loss of $0.18 per share on $566.68 million in revenue, shares of CONSOL are 2.6% in the green as investors look past the soft results. Given the rally in natural gas, and the potential prospect of a Trump Presidency, there are more reasons to own CONSOL Energy now that there were one quarter ago. A total of 33 funds from our database have a bullish position in CONSOL Energy Inc. (NYSE:CNX) as of the end of March.

Mobileye Drops on Tesla News

Although Mobileye NV (NYSE:MBLY) may have turned in a solid quarter with EPS of $0.17 on revenue of $83.48 million (beating estimates by $0.02 per share for the bottom line and exceeding the top-line by $6.17 million), shares of the company are more than 12% lower on news that the company’s partnership with Tesla Motors Inc (NASDAQ:TSLA) is closer to the end. According to various sources, Tesla won’t be using any new versions of Mobileye products beyond the currently-in-use EyeQ3. Tesla has received bad publicity from its self-driving feature which has led to several high profile accidents in recent weeks. The company will need to improve its product for autonomous driving to go mainstream. According to our data, smart money investors were less optimistic on Mobileye and 26 funds tracked by us had a bullish position in Mobileye NV (NYSE:MBLY) at the end of the first quarter, down by seven funds from the previous quarter.

Eli Lilly Reports Solid Quarter

Eli Lilly and Co (NYSE:LLY) showed why it is one of the most widely-held dividend stocks in the healthcare sector after reporting earnings of $0.86 per share on revenue of $5.4 billion for the second quarter. Given the strong and relatively inelastic demand, Eli Lilly’s earnings were in-line with analyst estimates, while the drug company’s revenues beat the expectations by $250 million. 2016 guidance is relatively unchanged, with management continuing to expect adjusted EPS of $3.50 to $3.60 on sales of $20.6 billion to $21.1 billion. At the end of March, 57 funds owned $3 billion worth of Eli Lilly and Co (NYSE:LLY)’s stock, which accounted for 3.80% of the float, versus 54 funds and $2.08 billion, respectively, a quarter earlier.

Disclosure: none